Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 178

1.

Microfluidic active loading of single cells enables analysis of complex clinical specimens.

Calistri NL, Kimmerling RJ, Malinowski SW, Touat M, Stevens MM, Olcum S, Ligon KL, Manalis SR.

Nat Commun. 2018 Nov 14;9(1):4784. doi: 10.1038/s41467-018-07283-x.

2.

Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma.

McBrayer SK, Mayers JR, DiNatale GJ, Shi DD, Khanal J, Chakraborty AA, Sarosiek KA, Briggs KJ, Robbins AK, Sewastianik T, Shareef SJ, Olenchock BA, Parker SJ, Tateishi K, Spinelli JB, Islam M, Haigis MC, Looper RE, Ligon KL, Bernstein BE, Carrasco RD, Cahill DP, Asara JM, Metallo CM, Yennawar NH, Vander Heiden MG, Kaelin WG Jr.

Cell. 2018 Sep 20;175(1):101-116.e25. doi: 10.1016/j.cell.2018.08.038. Epub 2018 Sep 13.

PMID:
30220459
3.

Vemurafenib and cobimetinib overcome resistance to vemurafenib in BRAF-mutant ganglioglioma.

Touat M, Gratieux J, Condette Auliac S, Sejean K, Aldea S, Savatovsky J, Perkins G, Blons H, Ligon KL, Idbaih A, Hollebecque A, Gimenez-Roqueplo AP, Laurent-Puig P, Sanson M, Villa C, Di Stefano AL.

Neurology. 2018 Sep 11;91(11):523-525. doi: 10.1212/WNL.0000000000006171. Epub 2018 Aug 17. No abstract available.

PMID:
30120137
4.

Correction to: DNA methylation-based reclassification of olfactory neuroblastoma.

Capper D, Engel NW, Stichel D, Lechner M, Glöss S, Schmid S, Kölsche C, Schrimpf D, Niesen J, Wefers AK, Jones DTW, Sill M, Weigert O, Ligon KL, Olar A, Koch A, Forster M, Moran S, Tirado OM, Sáinz-Jaspeado M, Mora J, Esteller M, Alonso J, Del Muro XG, Paulus W, Felsberg J, Reifenberger G, Glatzel M, Frank S, Monoranu CM, Lund VJ, von Deimling A, Pfister S, Buslei R, Ribbat-Idel J, Perner S, Gudziol V, Meinhardt M, Schüller U.

Acta Neuropathol. 2018 Sep;136(3):505. doi: 10.1007/s00401-018-1887-y.

PMID:
30094618
5.

A PDGFRα-driven mouse model of glioblastoma reveals a stathmin1-mediated mechanism of sensitivity to vinblastine.

Jun HJ, Appleman VA, Wu HJ, Rose CM, Pineda JJ, Yeo AT, Delcuze B, Lee C, Gyuris A, Zhu H, Woolfenden S, Bronisz A, Nakano I, Chiocca EA, Bronson RT, Ligon KL, Sarkaria JN, Gygi SP, Michor F, Mitchison TJ, Charest A.

Nat Commun. 2018 Aug 6;9(1):3116. doi: 10.1038/s41467-018-05036-4.

6.

The secreted glycolytic enzyme GPI/AMF stimulates glioblastoma cell migration and invasion in an autocrine fashion but can have anti-proliferative effects.

Kathagen-Buhmann A, Maire CL, Weller J, Schulte A, Matschke J, Holz M, Ligon KL, Glatzel M, Westphal M, Lamszus K.

Neuro Oncol. 2018 Nov 12;20(12):1594-1605. doi: 10.1093/neuonc/noy117.

PMID:
30053149
7.

Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort.

Iorgulescu JB, Harary M, Zogg CK, Ligon KL, Reardon DA, Hodi FS, Aizer AA, Smith TR.

Cancer Immunol Res. 2018 Sep;6(9):1039-1045. doi: 10.1158/2326-6066.CIR-18-0067. Epub 2018 Jul 12.

PMID:
30002157
8.

Dual HDAC and PI3K Inhibition Abrogates NFκB- and FOXM1-Mediated DNA Damage Response to Radiosensitize Pediatric High-Grade Gliomas.

Pal S, Kozono D, Yang X, Fendler W, Fitts W, Ni J, Alberta JA, Zhao J, Liu KX, Bian J, Truffaux N, Weiss WA, Resnick AC, Bandopadhayay P, Ligon KL, DuBois SG, Mueller S, Chowdhury D, Haas-Kogan DA.

Cancer Res. 2018 Jul 15;78(14):4007-4021. doi: 10.1158/0008-5472.CAN-17-3691. Epub 2018 May 14.

PMID:
29760046
9.

Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma.

Gupta N, Goumnerova LC, Manley P, Chi SN, Neuberg D, Puligandla M, Fangusaro J, Goldman S, Tomita T, Alden T, DiPatri A, Rubin JB, Gauvain K, Limbrick D, Leonard J, Geyer JR, Leary S, Browd S, Wang Z, Sood S, Bendel A, Nagib M, Gardner S, Karajannis MA, Harter D, Ayyanar K, Gump W, Bowers DC, Weprin B, MacDonald TJ, Aguilera D, Brahma B, Robison NJ, Kiehna E, Krieger M, Sandler E, Aldana P, Khatib Z, Ragheb J, Bhatia S, Mueller S, Banerjee A, Bredlau AL, Gururangan S, Fuchs H, Cohen KJ, Jallo G, Dorris K, Handler M, Comito M, Dias M, Nazemi K, Baird L, Murray J, Lindeman N, Hornick JL, Malkin H, Sinai C, Greenspan L, Wright KD, Prados M, Bandopadhayay P, Ligon KL, Kieran MW.

Neuro Oncol. 2018 Oct 9;20(11):1547-1555. doi: 10.1093/neuonc/noy070.

10.

DNA methylation-based reclassification of olfactory neuroblastoma.

Capper D, Engel NW, Stichel D, Lechner M, Glöss S, Schmid S, Koelsche C, Schrimpf D, Niesen J, Wefers AK, Jones DTW, Sill M, Weigert O, Ligon KL, Olar A, Koch A, Forster M, Moran S, Tirado OM, Sáinz-Jaspeado M, Mora J, Esteller M, Alonso J, Del Muro XG, Paulus W, Felsberg J, Reifenberger G, Glatzel M, Frank S, Monoranu CM, Lund VJ, von Deimling A, Pfister S, Buslei R, Ribbat-Idel J, Perner S, Gudziol V, Meinhardt M, Schüller U.

Acta Neuropathol. 2018 Aug;136(2):255-271. doi: 10.1007/s00401-018-1854-7. Epub 2018 May 5. Erratum in: Acta Neuropathol. 2018 Sep;136(3):505.

PMID:
29730775
11.

Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq.

Filbin MG, Tirosh I, Hovestadt V, Shaw ML, Escalante LE, Mathewson ND, Neftel C, Frank N, Pelton K, Hebert CM, Haberler C, Yizhak K, Gojo J, Egervari K, Mount C, van Galen P, Bonal DM, Nguyen QD, Beck A, Sinai C, Czech T, Dorfer C, Goumnerova L, Lavarino C, Carcaboso AM, Mora J, Mylvaganam R, Luo CC, Peyrl A, Popović M, Azizi A, Batchelor TT, Frosch MP, Martinez-Lage M, Kieran MW, Bandopadhayay P, Beroukhim R, Fritsch G, Getz G, Rozenblatt-Rosen O, Wucherpfennig KW, Louis DN, Monje M, Slavc I, Ligon KL, Golub TR, Regev A, Bernstein BE, Suvà ML.

Science. 2018 Apr 20;360(6386):331-335. doi: 10.1126/science.aao4750.

PMID:
29674595
12.

Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma.

Ellingson BM, Abrey LE, Nelson SJ, Kaufmann TJ, Garcia J, Chinot O, Saran F, Nishikawa R, Henriksson R, Mason WP, Wick W, Butowski N, Ligon KL, Gerstner ER, Colman H, de Groot J, Chang S, Mellinghoff I, Young RJ, Alexander BM, Colen R, Taylor JW, Arrillaga-Romany I, Mehta A, Huang RY, Pope WB, Reardon D, Batchelor T, Prados M, Galanis E, Wen PY, Cloughesy TF.

Neuro Oncol. 2018 Aug 2;20(9):1240-1250. doi: 10.1093/neuonc/noy053.

13.

Immunophenotyping of pediatric brain tumors: correlating immune infiltrate with histology, mutational load, and survival and assessing clonal T cell response.

Plant AS, Koyama S, Sinai C, Solomon IH, Griffin GK, Ligon KL, Bandopadhayay P, Betensky R, Emerson R, Dranoff G, Kieran MW, Ritz J.

J Neurooncol. 2018 Apr;137(2):269-278. doi: 10.1007/s11060-017-2737-9. Epub 2018 Jan 10.

PMID:
29322427
14.

The FDA NIH Biomarkers, EndpointS, and other Tools (BEST) resource in neuro-oncology.

Cagney DN, Sul J, Huang RY, Ligon KL, Wen PY, Alexander BM.

Neuro Oncol. 2018 Aug 2;20(9):1162-1172. doi: 10.1093/neuonc/nox242.

PMID:
29294069
15.

A novel GIT2-BRAF fusion in pilocytic astrocytoma.

Helgager J, Lidov HG, Mahadevan NR, Kieran MW, Ligon KL, Alexandrescu S.

Diagn Pathol. 2017 Nov 15;12(1):82. doi: 10.1186/s13000-017-0669-5.

16.

Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143.

Omuro A, Vlahovic G, Lim M, Sahebjam S, Baehring J, Cloughesy T, Voloschin A, Ramkissoon SH, Ligon KL, Latek R, Zwirtes R, Strauss L, Paliwal P, Harbison CT, Reardon DA, Sampson JH.

Neuro Oncol. 2018 Apr 9;20(5):674-686. doi: 10.1093/neuonc/nox208.

PMID:
29106665
17.

Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma.

Byron SA, Tran NL, Halperin RF, Phillips JJ, Kuhn JG, de Groot JF, Colman H, Ligon KL, Wen PY, Cloughesy TF, Mellinghoff IK, Butowski NA, Taylor JW, Clarke JL, Chang SM, Berger MS, Molinaro AM, Maggiora GM, Peng S, Nasser S, Liang WS, Trent JM, Berens ME, Carpten JD, Craig DW, Prados MD.

Clin Cancer Res. 2018 Jan 15;24(2):295-305. doi: 10.1158/1078-0432.CCR-17-0963. Epub 2017 Oct 26.

PMID:
29074604
18.

Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02.

Galanis E, Anderson SK, Miller CR, Sarkaria JN, Jaeckle K, Buckner JC, Ligon KL, Ballman KV, Moore DF Jr, Nebozhyn M, Loboda A, Schiff D, Ahluwalia MS, Lee EQ, Gerstner ER, Lesser GJ, Prados M, Grossman SA, Cerhan J, Giannini C, Wen PY; Alliance for Clinical Trials in Oncology and ABTC.

Neuro Oncol. 2018 Mar 27;20(4):546-556. doi: 10.1093/neuonc/nox161.

PMID:
29016887
19.

Salvage re-irradiation for recurrent high-grade glioma and comparison to bevacizumab alone.

Arvold ND, Shi DD, Aizer AA, Norden AD, Reardon DA, Lee EQ, Nayak L, Dunn IF, Golby AJ, Johnson MD, Claus EB, Chiocca EA, Ligon KL, Wen PY, Alexander BM.

J Neurooncol. 2017 Dec;135(3):581-591. doi: 10.1007/s11060-017-2611-9. Epub 2017 Oct 3.

PMID:
28975467
20.

Glioblastoma targeted therapy: updated approaches from recent biological insights.

Touat M, Idbaih A, Sanson M, Ligon KL.

Ann Oncol. 2017 Jul 1;28(7):1457-1472. doi: 10.1093/annonc/mdx106. Review.

21.

Brainstem angiocentric gliomas with MYB-QKI rearrangements.

D'Aronco L, Rouleau C, Gayden T, Crevier L, Décarie JC, Perreault S, Jabado N, Bandopadhayay P, Ligon KL, Ellezam B.

Acta Neuropathol. 2017 Oct;134(4):667-669. doi: 10.1007/s00401-017-1763-1. Epub 2017 Aug 12. No abstract available.

PMID:
28803398
22.

Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas.

Lassaletta A, Zapotocky M, Mistry M, Ramaswamy V, Honnorat M, Krishnatry R, Guerreiro Stucklin A, Zhukova N, Arnoldo A, Ryall S, Ling C, McKeown T, Loukides J, Cruz O, de Torres C, Ho CY, Packer RJ, Tatevossian R, Qaddoumi I, Harreld JH, Dalton JD, Mulcahy-Levy J, Foreman N, Karajannis MA, Wang S, Snuderl M, Nageswara Rao A, Giannini C, Kieran M, Ligon KL, Garre ML, Nozza P, Mascelli S, Raso A, Mueller S, Nicolaides T, Silva K, Perbet R, Vasiljevic A, Faure Conter C, Frappaz D, Leary S, Crane C, Chan A, Ng HK, Shi ZF, Mao Y, Finch E, Eisenstat D, Wilson B, Carret AS, Hauser P, Sumerauer D, Krskova L, Larouche V, Fleming A, Zelcer S, Jabado N, Rutka JT, Dirks P, Taylor MD, Chen S, Bartels U, Huang A, Ellison DW, Bouffet E, Hawkins C, Tabori U.

J Clin Oncol. 2017 Sep 1;35(25):2934-2941. doi: 10.1200/JCO.2016.71.8726. Epub 2017 Jul 20.

23.

Nuclear CRX and FOXJ1 Expression Differentiates Non-Germ Cell Pineal Region Tumors and Supports the Ependymal Differentiation of Papillary Tumor of the Pineal Region.

Coy S, Dubuc AM, Dahiya S, Ligon KL, Vasiljevic A, Santagata S.

Am J Surg Pathol. 2017 Oct;41(10):1410-1421. doi: 10.1097/PAS.0000000000000903.

PMID:
28719464
24.

Post-translational Modifications of OLIG2 Regulate Glioma Invasion through the TGF-β Pathway.

Singh SK, Fiorelli R, Kupp R, Rajan S, Szeto E, Lo Cascio C, Maire CL, Sun Y, Alberta JA, Eschbacher JM, Ligon KL, Berens ME, Sanai N, Mehta S.

Cell Rep. 2017 Jun 13;19(11):2410-2412. doi: 10.1016/j.celrep.2017.05.039. No abstract available.

25.

Clinical Identification of Oncogenic Drivers and Copy-Number Alterations in Pituitary Tumors.

Bi WL, Greenwald NF, Ramkissoon SH, Abedalthagafi M, Coy SM, Ligon KL, Mei Y, MacConaill L, Ducar M, Min L, Santagata S, Kaiser UB, Beroukhim R, Laws ER Jr, Dunn IF.

Endocrinology. 2017 Jul 1;158(7):2284-2291. doi: 10.1210/en.2016-1967.

26.

A Sequentially Priming Phosphorylation Cascade Activates the Gliomagenic Transcription Factor Olig2.

Zhou J, Tien AC, Alberta JA, Ficarro SB, Griveau A, Sun Y, Deshpande JS, Card JD, Morgan-Smith M, Michowski W, Hashizume R, James CD, Ligon KL, Snider WD, Sicinski P, Marto JA, Rowitch DH, Stiles CD.

Cell Rep. 2017 Mar 28;18(13):3167-3177. doi: 10.1016/j.celrep.2017.03.003.

27.

Leveraging molecular datasets for biomarker-based clinical trial design in glioblastoma.

Tanguturi SK, Trippa L, Ramkissoon SH, Pelton K, Knoff D, Sandak D, Lindeman NI, Ligon AH, Beroukhim R, Parmigiani G, Wen PY, Ligon KL, Alexander BM.

Neuro Oncol. 2017 Jul 1;19(7):908-917. doi: 10.1093/neuonc/now312.

28.

G1 cyclins link proliferation, pluripotency and differentiation of embryonic stem cells.

Liu L, Michowski W, Inuzuka H, Shimizu K, Nihira NT, Chick JM, Li N, Geng Y, Meng AY, Ordureau A, Kołodziejczyk A, Ligon KL, Bronson RT, Polyak K, Harper JW, Gygi SP, Wei W, Sicinski P.

Nat Cell Biol. 2017 Mar;19(3):177-188. doi: 10.1038/ncb3474. Epub 2017 Feb 13.

29.

Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas.

Shankar GM, Abedalthagafi M, Vaubel RA, Merrill PH, Nayyar N, Gill CM, Brewster R, Bi WL, Agarwalla PK, Thorner AR, Reardon DA, Al-Mefty O, Wen PY, Alexander BM, van Hummelen P, Batchelor TT, Ligon KL, Ligon AH, Meyerson M, Dunn IF, Beroukhim R, Louis DN, Perry A, Carter SL, Giannini C, Curry WT Jr, Cahill DP, Barker FG 2nd, Brastianos PK, Santagata S.

Neuro Oncol. 2017 Apr 1;19(4):535-545. doi: 10.1093/neuonc/now235.

30.

Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors.

Ramkissoon SH, Bandopadhayay P, Hwang J, Ramkissoon LA, Greenwald NF, Schumacher SE, O'Rourke R, Pinches N, Ho P, Malkin H, Sinai C, Filbin M, Plant A, Bi WL, Chang MS, Yang E, Wright KD, Manley PE, Ducar M, Alexandrescu S, Lidov H, Delalle I, Goumnerova LC, Church AJ, Janeway KA, Harris MH, MacConaill LE, Folkerth RD, Lindeman NI, Stiles CD, Kieran MW, Ligon AH, Santagata S, Dubuc AM, Chi SN, Beroukhim R, Ligon KL.

Neuro Oncol. 2017 Jul 1;19(7):986-996. doi: 10.1093/neuonc/now294.

31.

A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas.

Sun Y, Alberta JA, Pilarz C, Calligaris D, Chadwick EJ, Ramkissoon SH, Ramkissoon LA, Garcia VM, Mazzola E, Goumnerova L, Kane M, Yao Z, Kieran MW, Ligon KL, Hahn WC, Garraway LA, Rosen N, Gray NS, Agar NY, Buhrlage SJ, Segal RA, Stiles CD.

Neuro Oncol. 2017 Jun 1;19(6):774-785. doi: 10.1093/neuonc/now261.

32.

Nuclear inclusion bodies of mutant and wild-type p53 in cancer: a hallmark of p53 inactivation and proteostasis remodelling by p53 aggregation.

De Smet F, Saiz Rubio M, Hompes D, Naus E, De Baets G, Langenberg T, Hipp MS, Houben B, Claes F, Charbonneau S, Delgado Blanco J, Plaisance S, Ramkissoon S, Ramkissoon L, Simons C, van den Brandt P, Weijenberg M, Van England M, Lambrechts S, Amant F, D'Hoore A, Ligon KL, Sagaert X, Schymkowitz J, Rousseau F.

J Pathol. 2017 May;242(1):24-38. doi: 10.1002/path.4872. Epub 2017 Mar 23.

PMID:
28035683
33.

Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate.

Stevens MM, Maire CL, Chou N, Murakami MA, Knoff DS, Kikuchi Y, Kimmerling RJ, Liu H, Haidar S, Calistri NL, Cermak N, Olcum S, Cordero NA, Idbaih A, Wen PY, Weinstock DM, Ligon KL, Manalis SR.

Nat Biotechnol. 2016 Nov;34(11):1161-1167. doi: 10.1038/nbt.3697. Epub 2016 Oct 10.

34.

Pediatric low-grade gliomas: implications of the biologic era.

Packer RJ, Pfister S, Bouffet E, Avery R, Bandopadhayay P, Bornhorst M, Bowers DC, Ellison D, Fangusaro J, Foreman N, Fouladi M, Gajjar A, Haas-Kogan D, Hawkins C, Ho CY, Hwang E, Jabado N, Kilburn LB, Lassaletta A, Ligon KL, Massimino M, Meeteren SV, Mueller S, Nicolaides T, Perilongo G, Tabori U, Vezina G, Warren K, Witt O, Zhu Y, Jones DT, Kieran M.

Neuro Oncol. 2017 Jun 1;19(6):750-761. doi: 10.1093/neuonc/now209. Review.

35.

Genomic characterization of recurrent high-grade astroblastoma.

Bale TA, Abedalthagafi M, Bi WL, Kang YJ, Merrill P, Dunn IF, Dubuc A, Charbonneau SK, Brown L, Ligon AH, Ramkissoon SH, Ligon KL.

Cancer Genet. 2016 Jul-Aug;209(7-8):321-30. doi: 10.1016/j.cancergen.2016.06.002. Epub 2016 Jun 21.

PMID:
27425854
36.

Tyrosine receptor kinase B is a drug target in astrocytomas.

Ni J, Xie S, Ramkissoon SH, Luu V, Sun Y, Bandopadhayay P, Beroukhim R, Roberts TM, Stiles CD, Segal RA, Ligon KL, Hahn WC, Zhao JJ.

Neuro Oncol. 2017 Jan;19(1):22-30. doi: 10.1093/neuonc/now139. Epub 2016 Jul 10.

37.

Post-translational Modifications of OLIG2 Regulate Glioma Invasion through the TGF-β Pathway.

Singh SK, Fiorelli R, Kupp R, Rajan S, Szeto E, Lo Cascio C, Maire CL, Sun Y, Alberta JA, Eschbacher JM, Ligon KL, Berens ME, Sanai N, Mehta S.

Cell Rep. 2016 Jul 26;16(4):950-966. doi: 10.1016/j.celrep.2016.06.045. Epub 2016 Jul 7. Erratum in: Cell Rep. 2017 Jun 13;19(11):2410-2412.

38.

Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas.

Zhang B, Chang K, Ramkissoon S, Tanguturi S, Bi WL, Reardon DA, Ligon KL, Alexander BM, Wen PY, Huang RY.

Neuro Oncol. 2017 Jan;19(1):109-117. doi: 10.1093/neuonc/now121. Epub 2016 Jun 26.

39.

Glioproliferative Lesion of the Spinal Cord as a Complication of "Stem-Cell Tourism".

Berkowitz AL, Miller MB, Mir SA, Cagney D, Chavakula V, Guleria I, Aizer A, Ligon KL, Chi JH.

N Engl J Med. 2016 Jul 14;375(2):196-8. doi: 10.1056/NEJMc1600188. Epub 2016 Jun 22. No abstract available.

40.

Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases.

Ni J, Ramkissoon SH, Xie S, Goel S, Stover DG, Guo H, Luu V, Marco E, Ramkissoon LA, Kang YJ, Hayashi M, Nguyen QD, Ligon AH, Du R, Claus EB, Alexander BM, Yuan GC, Wang ZC, Iglehart JD, Krop IE, Roberts TM, Winer EP, Lin NU, Ligon KL, Zhao JJ.

Nat Med. 2016 Jul;22(7):723-6. doi: 10.1038/nm.4120. Epub 2016 Jun 6.

41.

MAPK activation and HRAS mutation identified in pituitary spindle cell oncocytoma.

Miller MB, Bi WL, Ramkissoon LA, Kang YJ, Abedalthagafi M, Knoff DS, Agarwalla PK, Wen PY, Reardon DA, Alexander BM, Laws ER Jr, Dunn IF, Beroukhim R, Ligon KL, Ramkissoon SH.

Oncotarget. 2016 Jun 14;7(24):37054-37063. doi: 10.18632/oncotarget.9244.

42.

Control of glioblastoma tumorigenesis by feed-forward cytokine signaling.

Jahani-Asl A, Yin H, Soleimani VD, Haque T, Luchman HA, Chang NC, Sincennes MC, Puram SV, Scott AM, Lorimer IA, Perkins TJ, Ligon KL, Weiss S, Rudnicki MA, Bonni A.

Nat Neurosci. 2016 Jun;19(6):798-806. doi: 10.1038/nn.4295. Epub 2016 Apr 25.

43.

Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma.

Nikbakht H, Panditharatna E, Mikael LG, Li R, Gayden T, Osmond M, Ho CY, Kambhampati M, Hwang EI, Faury D, Siu A, Papillon-Cavanagh S, Bechet D, Ligon KL, Ellezam B, Ingram WJ, Stinson C, Moore AS, Warren KE, Karamchandani J, Packer RJ, Jabado N, Majewski J, Nazarian J.

Nat Commun. 2016 Apr 6;7:11185. doi: 10.1038/ncomms11185.

44.

MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism.

Bandopadhayay P, Ramkissoon LA, Jain P, Bergthold G, Wala J, Zeid R, Schumacher SE, Urbanski L, O'Rourke R, Gibson WJ, Pelton K, Ramkissoon SH, Han HJ, Zhu Y, Choudhari N, Silva A, Boucher K, Henn RE, Kang YJ, Knoff D, Paolella BR, Gladden-Young A, Varlet P, Pages M, Horowitz PM, Federation A, Malkin H, Tracy AA, Seepo S, Ducar M, Van Hummelen P, Santi M, Buccoliero AM, Scagnet M, Bowers DC, Giannini C, Puget S, Hawkins C, Tabori U, Klekner A, Bognar L, Burger PC, Eberhart C, Rodriguez FJ, Hill DA, Mueller S, Haas-Kogan DA, Phillips JJ, Santagata S, Stiles CD, Bradner JE, Jabado N, Goren A, Grill J, Ligon AH, Goumnerova L, Waanders AJ, Storm PB, Kieran MW, Ligon KL, Beroukhim R, Resnick AC.

Nat Genet. 2016 Mar;48(3):273-82. doi: 10.1038/ng.3500. Epub 2016 Feb 1.

45.

Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma.

Abedalthagafi M, Bi WL, Aizer AA, Merrill PH, Brewster R, Agarwalla PK, Listewnik ML, Dias-Santagata D, Thorner AR, Van Hummelen P, Brastianos PK, Reardon DA, Wen PY, Al-Mefty O, Ramkissoon SH, Folkerth RD, Ligon KL, Ligon AH, Alexander BM, Dunn IF, Beroukhim R, Santagata S.

Neuro Oncol. 2016 May;18(5):649-55. doi: 10.1093/neuonc/nov316. Epub 2016 Jan 28.

46.

Case Report: Next generation sequencing identifies a NAB2-STAT6 fusion in Glioblastoma.

Diamandis P, Ferrer-Luna R, Huang RY, Folkerth RD, Ligon AH, Wen PY, Beroukhim R, Ligon KL, Ramkissoon SH.

Diagn Pathol. 2016 Jan 27;11:13. doi: 10.1186/s13000-016-0455-9.

47.

Targetable genetic features of primary testicular and primary central nervous system lymphomas.

Chapuy B, Roemer MG, Stewart C, Tan Y, Abo RP, Zhang L, Dunford AJ, Meredith DM, Thorner AR, Jordanova ES, Liu G, Feuerhake F, Ducar MD, Illerhaus G, Gusenleitner D, Linden EA, Sun HH, Homer H, Aono M, Pinkus GS, Ligon AH, Ligon KL, Ferry JA, Freeman GJ, van Hummelen P, Golub TR, Getz G, Rodig SJ, de Jong D, Monti S, Shipp MA.

Blood. 2016 Feb 18;127(7):869-81. doi: 10.1182/blood-2015-10-673236. Epub 2015 Dec 23.

48.

Decreased FOXJ1 expression and its ciliogenesis programme in aggressive ependymoma and choroid plexus tumours.

Abedalthagafi MS, Wu MP, Merrill PH, Du Z, Woo T, Sheu SH, Hurwitz S, Ligon KL, Santagata S.

J Pathol. 2016 Mar;238(4):584-97. doi: 10.1002/path.4682.

49.

A Brain Tumor/Organotypic Slice Co-culture System for Studying Tumor Microenvironment and Targeted Drug Therapies.

Chadwick EJ, Yang DP, Filbin MG, Mazzola E, Sun Y, Behar O, Pazyra-Murphy MF, Goumnerova L, Ligon KL, Stiles CD, Segal RA.

J Vis Exp. 2015 Nov 7;(105):e53304. doi: 10.3791/53304.

50.

Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model.

Reardon DA, Gokhale PC, Klein SR, Ligon KL, Rodig SJ, Ramkissoon SH, Jones KL, Conway AS, Liao X, Zhou J, Wen PY, Van Den Abbeele AD, Hodi FS, Qin L, Kohl NE, Sharpe AH, Dranoff G, Freeman GJ.

Cancer Immunol Res. 2016 Feb;4(2):124-35. doi: 10.1158/2326-6066.CIR-15-0151. Epub 2015 Nov 6.

Supplemental Content

Loading ...
Support Center